Previous close | 198.35 |
Open | 197.08 |
Bid | 190.00 x 1200 |
Ask | 202.99 x 800 |
Day's range | 197.01 - 200.15 |
52-week range | 179.59 - 234.09 |
Volume | |
Avg. volume | 781,301 |
Market cap | 16.725B |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | 42.94 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.45%) |
Ex-dividend date | 28 May 2024 |
1y target est | N/A |
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2024 and updated full-year guidance.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.
Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis for $239 million in cash consideration, plus other non-cash consideration.